

# Publish your next article in the **Journal of the International AIDS Society**

[www.jiasociety.org](http://www.jiasociety.org)

**SUBMIT**



Online HIV/AIDS journal • Open access • Peer-reviewed  
PubMed and MEDLINE indexed • Operational Research encouraged

• Peer-reviewed  
• Online HIV/AIDS journal  
• Open access

• PubMed and MEDLINE indexed • Operational Research encouraged

Online HIV/AIDS journal Open access Peer-reviewed PubMed and MEDLINE indexed  
HIV/AIDS journal Open access Peer-reviewed PubMed and MEDLINE indexed Op  
Peer-reviewed PubMed and MEDLINE indexed Operational Research encouraged  
PubMed and MEDLINE indexed Operational Research encour

## WEPL01 Wednesday Plenary Session

Plenary Session

**Venue:** Session Room 1

**Time:** Wednesday 03 July, 08:55-10:30

**Co-Chairs:** Eric Goosby, United States  
Jean-Francois Delfraissy, France  
Julio Montaner, Canada

### Award Presentation: IAS/ANRS Young Investigator Award and IAS/ANRS Young Investigator Award-Special HIV Cure Prize

*F. Barré-Sinoussi, France; J. Delfraissy, France; F. Barré-Sinoussi, France; J. Delfraissy, France*

**Tracking the HIV Epidemic in Asia and the Pacific**  
*J. Prasada Rao, UNAIDS*

**Vaccine: New Developments in Protecting Antibodies**

*D. Burton, United States*

**HCV in HIV patients: cure and beyond**

*K. Lacombe, France*

## WEAB01 Reach for the Top: Can We Perfect Current ART?

Oral Abstract Session

**Venue:** Session Room 1

**Time:** Wednesday 03 July, 11:00-12:30

**Co-Chairs:** Robert Murphy, United States  
Sasisopin Kiertburanakul, Thailand

### Impact of 12 months HAART on cell-associated HIV-DNA in acute primary HIV-1 infection in the OPTIPRIM-ANRS 147 trial

*A. Chéret, G. Nembot, V. Avettand-fenoël, A. Mélard, I. Ravaux, B. Hoen, C. Lascoux-Combe, M.-L. Chaix, C. Tamalet, P. Yeni, F. Raffi, L. Slama, C. Katlama, A. Venet, B. Autran, A. Saez-Cirion, L. Meyer, C. Rouzioux, France*

### In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm3 achieves better HIV-1 reservoirs' depletion and T cell count restoration

*L. Hocqueloux, V. Avettand-Fenoël, T. Prazuck, A. Mélard, E. Legac, M. Niang, C. Mille, J. Buret, C. Rouzioux, "Coordinated Action on HIV Reservoirs" (AC32) of the ANRS (Agence Nationale de Recherches sur le Sida et les hépatites virales), France*

### First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety and tolerability in healthy adults

*W. Spreen, P. Williams, D. Margolis, S. Ford, H. Crauwels, Y. Lou, E. Gould, M. Stevens, S. Piscitelli, United States*

### Efficacy of initial antiretroviral therapy: a meta-analysis of 40,124 adults with up to 144 weeks' follow-up

*F. J. Lee, J. Amin, A. Carr, Australia*

### Long term therapeutic success of etravirine in switch and naive patients

*L. Bull, M. Bower, M. Nelson, United Kingdom*

**Moderated discussion**

## WEAC01 Three A's of Chemoprophylaxis: Acceptability, Access and Adherence

Oral Abstract Session

**Venue:** Session Room 2

**Time:** Wednesday 03 July, 11:00-12:30

**Co-Chairs:** Valdiléa Veloso, Brazil  
Jean-Michel Molina, France

### Pregnancy incidence and birth outcomes among African women in a clinical trial of pre-exposure prophylaxis: the Partners PrEP Study

*N. Mugo, T. Hong, C. Celum, D. Donnell, E. Bukusi, E. Were, G. John-Stewart, J. Baeten, Partners PrEP Study, Kenya*

### MSM in Latin America, Spain and Portugal using an internet social networking site have limited awareness but high interest in pre-exposure prophylaxis to prevent sexual acquisition of HIV

*M. Mimiaga, K. Biello, D. Novak, J. Rosenberger, K. Mayer, United States*

### Adherence to rectal microbicide use among mainly ethnic minority young men who have sex with men (MSM): lessons from a 3-month placebo gel trial at three US sites

*A. Carballo-Diéguez, R. Giguere, J. Bauermeister, C. Dolezal, T. Frasca, C.-S. Leu, J. Valladares, I. Febo, R. Cranston, K. Mayer, I. McGowan, United States*

### Participant motivation for enrolling and continuing in the FEM-PrEP HIV prevention clinical trial

*C. Wong, C. Parker, K. Ahmed, K. Agot, J. Skhosana, J. Odhiambo, S. Makatu, A. Lemons, M. Mueller, L. Van Damme, A. Corneli, for the FEM-PrEP Study Group, United States*

### Comparison of adherence with pre-exposure prophylaxis among HIV-1-negative clinical trial participants in serodiscordant relationships in Kisumu before and after release of the trial results

*B. Wamuti, J. Odoyo, B. Rono, C. Cohen, E. Bukusi, Kenya*

**Moderated discussion**

## WESY01 Growing Up with HIV: Transitioning Adolescents to Adult Care

Symposia Session

**Venue:** Session Room 3

**Time:** Wednesday 03 July, 11:00-12:30

**Chair:** Annette Sohn, Thailand

Please note that to protect the privacy of the young speakers in this session, photographs will not be allowed.

This session is directed to clinicians and health care personnel who care for children and youth with perinatal HIV infection. Youth from the developing world will reflect on their experiences growing up with HIV. Then strategies to optimize antiretroviral therapy (ART) and promote adherence as well as diagnosis and management of complications from ART will be reviewed. Finally, the session will discuss approaches to HIV cure in perinatally infected population on long-term treatment. At the completion of the session, participants will be knowledgeable about the multi-faceted issues affecting youth with perinatally acquired HIV and interventions that could improve their quality of life and clinical outcomes.

### Introduction

#### Growing up with HIV in Asia I

*P.ZZ, Thailand*

#### Growing up with HIV in Asia II

*B.ZZ, Thailand*

### Questions and answers

#### Regimen selection, sequencing, and adherence in youth with perinatally acquired HIV infection

*G. Tudor-Williams, United Kingdom*

#### Complications of HIV and its treatment in perinatally infected adolescents

*T. Puthanakit, Thailand*

#### Approaches to HIV cure in children and youth with perinatal HIV infection

*D. Persaud, United States*

### Questions and answers

## WEAD01 Show Me the Money: Micro and Macro Approaches

Oral Abstract Session

**Venue:** Session Room 4

**Time:** Wednesday 03 July, 11:00-12:30

**Co-Chairs:** David Wilson, Australia

Ng Chiu Wan, Malaysia

## Return on investment of HIV harm reduction programmes for injecting drug users in Malaysia

*H. Nanning, C. Kerr, A. Kamarulzaman, M. Dahlui, N. Chiu Wan, D. Wilson*  
Malaysia

## The impact of a limited subsidy on access to antiretroviral therapy (ART) and patient outcomes in Singapore

*B. Young, L.P. Ho, C.C. Lee, Y.S. Leo, O.T. Ng, A. Chua*  
Singapore

## Cost-effectiveness of early infant HIV diagnosis and immediate antiretroviral therapy in HIV-infected children in Thailand

*I.J. Collins, J. Cairns, N. Ngo-Giang-Huong, W. Sirirungsi, P. Leechanachai, S. Le Coeur, N. Kamonpakorn, J. Mekmullica, G. Jourdain, M. Lallemand, PHPT Study Group*  
United Kingdom

## Affordability of HIV/AIDS treatment in developing countries: modeling ARV drug price determinants for a better understanding of the market functioning

*L. Sagaon Teyssier, Y. Arrighi, B. Dongmo-Nguimfack, J.-P. Moatti*  
France

## Allocation of global HIV program inputs to hard-to-reach and resource-poor districts of Uganda, 2005-2010

*T. Lim, B. Stover, N. Borse, E. Mukooyo, F. Makumbi, A. Hagopian*  
United States

### Moderated discussion

#### WEWS01 Breaking Through Stigma: The Missing Component in Biomedical Prevention Efforts

Professional Development Workshop

**Venue:** Mini Room 4

**Time:** Wednesday 03 July, 11:00-12:30

**Level:** Advanced

**Target audience:** Other health care worker / social services provider, Researcher, Policy specialist

**Seating limit:** 80

**Co-Facilitators:** Beena Thomas, India  
Ron Stall, United States

Many countries in Asia are facing concentrated epidemics amongst key at risk populations including men who have sex with men, female sex workers, transgenders, and people who use drugs. Providing HIV prevention and treatment services to them are hampered because stigma makes people difficult to reach. New methods to reach such hidden populations are being tried and strategies are being developed to combat stigma both at the community level and the policy level. The workshop will provide a timely platform to share views, experiences and research findings on the many ways in which stigma affects the HIV response, personal and social factors that can attenuate stigma experiences, and promising approaches to curb it. An international panel will give brief introductory presentations. Time will be reserved for a facilitated discussion between panelists and participants.

#### Introduction

*R. Stall, United States; R. Stall, United States*

#### Overcoming stigma: an individual struggle

*R. Samuel, Malaysia*

#### Influence of HIV-related and Sexual Minority Stigma on Mental Health and Sexual Risk Behaviors of MSM and Transgender people in India

*V. Chakrapani, India*

#### Socially constructed exclusion: understanding and mitigating the pervasive influences of HIV-related stigma

*J. De Wit, Australia*

#### Reducing HIV-related stigma among key populations: global lessons and key questions for biomedical prevention efforts

*M. Das, India*

### Moderated discussion

#### Closing remarks

*B. Thomas, India; B. Thomas, India*

#### WEME01 Meet the HIV and TB Experts

Meet the Experts

**Venue:** Session Room 3

**Time:** Wednesday 03 July, 12:45-14:00

**Seating limit:** 60

**Chair:** Linda-Gail Bekker, South Africa

The HIV and TB co-epidemic has provided challenges in management at the individual as well as public health levels. In this session a panel of HIV/TB experts will discuss challenging scenarios commonly confronting clinicians and public health officials alike. The audience will have opportunities to ask questions throughout the session and to engage directly with the panel of experts.

#### Panellists:

*J. Lundgren, Denmark; O. Kirk, Denmark; P. Godfrey-Faussett, UNAIDS; F. Altice, United States*

#### Case studies

#### WESS01 Dealing with Co-Morbidities of Chronic HIV: HPV-Related Cancers and Cardiovascular Disease

Special Session

**Venue:** Session Room 2

**Time:** Wednesday 03 July, 13:00-14:00

**Co-Chairs:** Andrew Grulich, Australia  
Peter Reiss, Netherlands

Human papillomavirus (HPV) causes a range of cancers in women and men. Although rates of cervical cancer have declined in higher-income settings, screening programmes in low and middle-income settings remain difficult to implement. Anal cancer rates in both men and women are rising, but there are few treatment options and ongoing disagreement about whether to screen and treat at all. HIV-infected individuals also are at increased risk of cardiovascular disease (CVD) including myocardial, endocardial, pericardial and vascular diseases. The pathophysiology is multi-factorial. Traditional cardiovascular risk factors, and dyslipidemia and insulin resistance associated with antiretroviral medications, have been implicated in acute ischemic events, whereas chronic inflammation together with immune activation is associated with vascular dysfunction and atherothrombosis. Prevention, diagnosis and treatment of CVD earlier in age are critical in HIV-infected individuals. This session will provide a high-level review of two key co-morbidities of chronic HIV infection.

#### Introduction

*A. Grulich, Australia; A. Grulich, Australia*

#### Catching up on HPV-related cancers: diagnostic advances and treatment controversies

*N. Phanuphak, Thailand*

#### Questions and answers

#### Introduction

*P. Reiss, Netherlands; P. Reiss, Netherlands*

#### Cardiovascular complications in HIV infected individuals in developed and developing countries

*M. Boyd, Australia*

#### Questions and answers

#### WEPDA01 Myeloid Cells Matter

Oral Poster Discussion Session

**Venue:** Mini Room 1

**Time:** Wednesday 03 July, 13:00-14:00

**Co-Chairs:** Suzanne Crowe, Australia  
Mariangela Cavarelli, Italy



**Introduction**

S.Crowe, Australia

**Glut1 expression on intermediate monocytes is a potential marker of inflammation in HIV-positive subjects**

J. Anzinger, J. Zhou, L. Lam, M. Gouillou, J. McCune, A. Jaworowski, S. Crowe, C. Palmer  
Jamaica

**HIV-1 virion accumulation and ATP-Induced release in human primary monocyte-derived macrophages**

F. Graziano, L. Garzetti, R. Furlan, M. Alfano, G. Poli  
Italy

**Anti-mycobacterial activity is enhanced by blocking the Tim3-Galectin 9 interaction in HIV patients**

M.I. Sada-Ovalle, R. Ocaña Guzmán, L. Chavéz Galán, J. Sierra Madero, S. Pérez-Patrigéon, M. Addo  
Mexico

**Monocyte gene expression differentiates cases of tuberculosis-associated immune reconstitution inflammatory syndrome from controls both before and shortly after initiation of combined antiretroviral therapy**

H.T.T. Tran, R. Van den Bergh, N.T. Vu, K. Laukens, W. Worodria, R. Colebunders, L. Kestens, G. Raes, P. De Baetselier, TB-IRIS study group  
Belgium

**Conclusion**

M.Cavarelli, Italy

**Moderated discussion**

**WEPDD01 Delivering Better Quality HIV Services**

Oral Poster Discussion Session

**Venue:** Mini Room 2

**Time:** Wednesday 03 July, 13:00-14:00

**Co-Chairs:** Bruce Agins, United States  
Do Mai Hoa, Vietnam

**Using continuous quality improvement approaches to identify facility-based innovations for increasing retention of TB/HIV co-infected patients on treatment in Uganda**

K. Mutesasira, D. Murdoch, N. Tumwesigye, A. Muhwezi, A. Musisi, M. Irige, H. Mutabarara, E. Alunguru, S. Muchuro  
Uganda

**Implementation of a quality improvement process to improve provider performance in care and treatment of people living with HIV**

J. Banda, W. Kanjipite, P. Njobvu, K. Adiedu, J. Nikisi, Y.M. Kim, S. Sarkar, E.B. Bazant, S. Reinhardt, C. Hiner, M. Tholandi, A. Kols, B. Benavides  
Zambia

**Clinical mentorship of nurse-initiated antiretroviral therapy (ART) in Khayelitsha, South Africa: a quality of care assessment**

A. Green, V. de Azevedo, G. Patten, M.-A. Davies, M. Ibeto, V. Cox  
South Africa

**Strengthening the gender focus to improve ANC/PMTCT service quality in Ethiopia**

N. Matinhure, B. Mohammed, M. Gebre, D. Belete, Z. Zegeye  
Ethiopia

**Improved quality of care through provincial wide capacity building**

D. Huong, T. Nguyen, H. Huyen, J. Pollack, D. Nguyen, P. Do, H. Libman, L. Hirschhorn, L. Cosimi  
Vietnam

**Moderated discussion**

**WEPDC01 Female Sex Workers: Complex Challenges and Emerging Opportunities**

Oral Poster Discussion Session

**Venue:** Mini Room 3

**Time:** Wednesday 03 July, 13:00-14:00

**Chair:** Stefan Baral, United States

**Risk factors of sexually transmitted infections (STI) and their relationship with HIV among female sex workers (FSW) in Nagaland, a high HIV prevalence state in India**

G.K. Medhi, J. Mahanta, S. Phukan, P. Goswami, R. Paranjape, KRIPA Foundation, Kohima  
India

**Six-month follow-up data from RCT testing brief alcohol reduction intervention with female sex workers in Mombasa, Kenya**

K. L'Engle, P. Mwarogo, N. Kingola, W. Sinkele  
Kenya

**Are street-based female sex workers a decent representative of brothel-based ones? A national cross sectional study in Iran**

R. Khajehkazemi, M. Karamouzian, A.A. Haghdooost  
Islamic Republic of Iran

**Determinants of the low uptake of HIV-related intervention services by female sex workers in Shenzhen, China: an observational study (2009-2012)**

R. Cai, J. Tan, J.H. Richardus, S. de Vlas  
Netherlands

**Reconceptualizing HIV prevention needs in a generalized epidemic: the case of female sex workers (FSW) in Swaziland**

S. Baral, S. Ketende, P.-A. Chen, C. Kennedy, Z. Mnisi, D. Adams, E. Yam, B. Sithole, X. Mabuza, D. Kerrigan  
United States

**Social cohesion, social participation and HIV related risk among female sex workers in Swaziland**

V. Fonner, D. Kerrigan, Z. Mnisi, S. Ketende, C. Kennedy, S. Baral  
United States

**Moderated discussion**

**WEPDB01 STIs and HIV: Dangerous Liaisons**

Oral Poster Discussion Session

**Venue:** Mini Room 4

**Time:** Wednesday 03 July, 13:00-14:00

**Co-Chairs:** Joshua Kimani, Kenya  
Rachel Baggaley, WHO

**Prevalence of Chlamydia trachomatis and Neisseria gonorrhoea infection by anatomic site in a cohort study of men who have sex with men (MSM) in Bangkok, Thailand**

W. Chonwattana, J. Tongtoyai, C.S. Todd, S. Pattanasin, S. Chaikummao, P. Wasinrapee, A. Varangrat, S. Lokpichart, T. Holtz, A. Chitwarakorn, M. Curlin  
Thailand

**A bio behavioural and prevalence study of HIV, syphilis and hepatitis B in high-risk men who have sex with men (MSM) in Kuala Lumpur, Malaysia**

I. Azwa, E. Celaya, I. Yee, K. Baker, S.H. Lim, A. Ashraf, F.T. Tai, M. Choo Kok Keong  
Malaysia

**Prevalence of anal human papillomavirus (HPV) infection and anal squamous intraepithelial lesions (SIL) in a cohort of Brazilian HIV-infected women**

B. Grinsztejn, R. Khalili, V. Veloso, B. Hoagland, S. Wagner, M. Derrico, C. Cunha, C. Barillo, A. Andrade, A. Cytrin, P. Luz, J.R. Coutinho  
Brazil

**High prevalence, incidence and clearance of anal high-grade squamous intraepithelial lesion (HSIL): early evidence from a natural history study in homosexual men**

E. Jin, I.M. Poynten, D. Machalek, J. Roberts, A. Farnsworth, R.J. Hillman, D.J. Templeton, S.N. Tabrizi, S.M. Garland, C. Fairley, A.E. Grulich, on behalf of the SPANC Study Team  
Australia

**Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behaviour: a meta-analytical review**

J.S. Doyle, L. Degenhardt, A. Pedrana, E. McBryde, R. Guy, M. Stoope, E. Weaver, A. Grulich, Y.-R. Lo, M.E. Hellard  
Australia

**Shigella flexneri enteritis in risk-taking HIV-infected MSM: a single institution experience**

M. Abdul-Latif, H. Beckett, M. Rayment, G.K. Jagjit Singh, M. Bower, M. Nelson  
United Kingdom

**Moderated discussion**

**WESY02 Treatment as Prevention in Asia: Progress and Challenges**

Symposia Session

**Venue:** Session Room 1

**Time:** Wednesday 03 July, 14:30-16:00

**Chair:** Nagalingeswaran Kumarasamy, India

HPTN 052 and multiple ecological and cohort studies have suggested that expansion of HIV treatment may be able to decrease new HIV transmissions. This session will provide an update regarding recent developments in HIV prevention efforts in southeast Asia and in specific countries and will review current progress in specific components of treatment as prevention including expanded HIV testing, diagnosis, linkage to and engagement in care, access to and uptake of treatment, initiation of ART as per local guidelines, as well as prevention for HIV-positive persons in care. Presenters will review recent changes in epidemiological trends in key populations and best practices in engaging HIV-positive persons in care and prevention activities, while ensuring that human rights are fully respected. The session will also analyze challenges for programme implementation, from limitations in resources and infrastructure, to persistent stigma, and lack of public awareness. Culturally appropriate examples of recent successes in Asia will be highlighted to provide lessons learned for participants.

## Introduction

### Treatment as prevention in southeast Asia

Y.Lo, WHO

### The Chinese experience with treatment as prevention

F.Zhang, China

### The Indian experience with treatment as prevention

B.Rewari, India

### The Vietnamese experience with treatment as prevention

B.Duong, Vietnam

## Questions and answers

### WEAB02 Organ Dysfunction in HIV: It's Complicated

Oral Abstract Session

**Venue:** Session Room 2

**Time:** Wednesday 03 July, 14:30-16:00

**Co-Chairs:** Chureeratana Bowonwatanuwong, Thailand  
Judith Feinberg, United States

### Tenofovir nephrotoxicity in resource-limited setting of western India: higher rate of renal function decline, acute kidney injury and progression to chronic kidney disease compared to western data

A. Dravid, A. Sadre, S. Dhande, A. Borkar, M. Kulkarni, M. Dravid  
India

### Effects on renal function of a switch from tenofovir (TDF) to abacavir (ABC)-based highly active antiretroviral therapy (HAART), with or without atazanavir

M. Harris, S. Guillemi, K. Chan, B. Yip, M. Hull, V. Dias Lima, R. Hogg, J. Montaner  
Canada

### HIV and HCV infections independently contribute to lower bone mineral density but have different effects on bone turnover markers

N. Maalouf, H. Drechsler, S. Zhang, J. Cutrell, G. Brown, I. Farukhi, P. Tebas, R. Bedimo  
United States

### HIV infection was associated with an increased risk of hip fracture, independently of age, gender and co-morbidities: a population-based cohort study

H. Knobel, R. Güerri, D. Prieto, J. Villar, A. Díez, E. Lerma, M. Montero, A. González, A. Guelar  
Spain

### Independent predictors of carotid intimal thickness differ between HIV+ and HIV- patients with respect to traditional cardiac risk factors, risk calculators, lipid subfractions and inflammatory markers

R. Hsu, K. Patton, J. Liang, R. Okabe, J. Aberg, N. Fineberg  
United States

## Moderated discussion

### WEAA01 Innate and Intrinsic Regulation of Viral Replication: Catch Me if You Can

Oral Abstract Session

**Venue:** Session Room 3

**Time:** Wednesday 03 July, 14:30-16:00

**Co-Chairs:** Florence Margottin-Goguet, France  
Damian Purcell, Australia

### What makes the transmitted HIV-1 in newly infected patients unique from the donor inoculum?

E. Arts, R. Shattock, A. Ratcliff, G. Nickel, I. Nankya, M. Lobritz, Y. Gao  
United States

### Dendritic cell-lymphocyte crosstalk stimulates HIV-1 replication and impairs host restriction factor SAMHD1 in dendritic cells

B. Su, M.E. Biedma, T. Decoville, A. Lederle, M. Peressin, M. Lambotin, A. Proust, S. Schmidt, G. Laumond, V. Holl, C. Moog  
France

### Cell-intrinsic HIV-1 immune responses in conventional dendritic cells from HIV-1 elite controllers

E. Martin-Gayo, T. Hickman, D. Pimenova, F. Pereyra, E. Rosenberg, B. Walker, M. Lichterfeld, X. Yu  
United States

### The intestinal microenvironment affects the susceptibility of DCs to HIV-1

M. Cavarelli, B. Fusetti, K. Tsilingiri, M. Rescigno, G. Scarlatti  
Italy

### The repression of the dNTP biosynthetic enzyme RNR2 by p21 restricts HIV-1 and related lentiviruses reverse transcription in macrophages

A. Allouch, A. David, S. Amie, H. Lahouassa, F. Margottin-Goguet, F. Barré-Sinoussi, A. Sáez-Cirión, B. Kim, G. Pancino  
France

## Moderated discussion

### WESY03 Integration and its Discontents

Symposia Session

**Venue:** Session Room 4

**Time:** Wednesday 03 July, 14:30-16:00

**Co-Chairs:** Elvin Geng, United States  
Nancy Padian, United States

Although integration of HIV services with general primary and other health care is an accepted objective and aspirational goal for building on existing HIV/AIDS health platforms, few rigorous evaluations of possible pitfalls or limitations have been conducted. This session will review the successes and challenges of integrating HIV services with other health services (e.g., antenatal care, general primary care, reproductive health care, tuberculosis care) from the perspective of efficiency and effectiveness. It will in particular address the following outstanding issues: Do vertical HIV programmes provide higher quality of care than existing general health services and will integration compromise the quality of care for HIV specific services? Given the heterogeneity of epidemiologic and programmatic settings, are there context specific differences in relative advantages and disadvantages of integrating health services? As integration of HIV services into general primary or other health care requires health workers to take on additional tasks, how can this expansion of responsibilities be sustained within overall resource constraints while maintaining quality of care? Is it necessary to first conduct additional research to examine the most effective and efficient models of integration and if so, what are the essential directions of future inquiry?

## Introduction

### Levelling vertical programmes: The natural evolution of integrated services within PEPFAR

E. Goosby, United States

### Integrating antenatal care and HIV services

E. Bukusi, Kenya

### Integrated services and their impact on service satisfaction

T. Odeny, Kenya

## Integration at a community level

*L.Guay, United States*

## **Integrating HIV services with primary health care**

*B.Agins, United States*

### **Panel discussion**

*B.Agins, United States; E.Bukusi, Kenya; E.Goosby, United States; T.Odeny, Kenya; L.Guay, United States; B.Agins, United States; E.Bukusi, Kenya; E.Goosby, United States; L.Guay, United States; T.Odeny, Kenya*

## **WEWS02 The Mysteries of Assessing Value For Money in HIV Service Delivery Unlocked: Principles, Group Exercises and Examples**

Professional Development Workshop

**Venue:** Mini Room 1

**Time:** Wednesday 03 July, 14:30-17:30

**Level:** Intermediate

**Target audience:** Policy/Administration, Policy / programme analyst, Researcher

**Seating limit:** 100

**Co-Facilitators:** Sergio Bautista Arredondo, Mexico  
Mead Over, United States  
Michelle Remme, United Kingdom

Value for money is the evaluation buzzword du jour, which can assume different meanings and be implemented with different tools. This workshop will provide an overview of the concept of "Value for Money" as it is currently being used by international donors and stakeholders and then walk participants through some of the basic calculations of costs and of "value" that would be part of an ex ante "value-for-money assessment" of a proposed health service delivery project. Finally, workshop facilitators will lead a critical discussion of the application of costing and cost-effectiveness analysis in three or four recently published papers. Participants are asked to bring laptop computers with a spreadsheet program like Excel and a fully charged battery to the session and be prepared to work, individually or in groups, on calculations on cost and cost-effectiveness exercises – and then to discuss the interpretation of their results.

### **Introduction**

#### **Overview of the term "value for money" and its relationship to the principles of costing and cost-effectiveness analysis with application to HIV/AIDS**

*S.Bautista Arredondo, Mexico*

#### **Group exercises in costing and cost-effectiveness analysis for HIV/AIDS using Excel**

*M.Over, United States; M.Over, United States*

#### **Exercises and discussion on recent research assessing the value for money as applied to HIV/AIDS interventions**

*M.Remme, United Kingdom*

### **Closing remarks**

## **WEWS03 Linking Clinical Cohorts and Basic/Clinical Science in Developing Countries**

Professional Development Workshop

**Venue:** Mini Room 2

**Time:** Wednesday 03 July, 14:30-17:30

**Level:** Intermediate

**Target audience:** Physician, Researcher, Clinical scientist, Basic scientist, Health care worker

**Seating limit:** to be confirmed

**Co-Facilitators:** Marcus Altfeld, United States  
Linda-Gail Bekker, South Africa

This workshop will briefly examine the establishment of clinical cohort studies and discuss critical concepts for establishing clinical cohorts, conducting clinical cohort studies and related ethical issues. A round table discussion will outline the contribution and experience of scientists in and from developing countries. Funding resources and training possibilities for scientists in developing countries will be addressed. This will be an interactive session with opportunity throughout for audience participation and discussion. At the end of the workshop the participants will know about processes needed to set up a clinical cohort study and maintain it and will understand the issues around basic and clinical science set ups in resource-limited countries.

### **Introduction**

#### **How and why?**

*L.Bekker, South Africa*

#### **Bringing basic science into the mix**

*M.Altfeld, United States*

#### **Answering the big questions**

*S.Lewin, Australia*

#### **Challenges and pitfalls**

*E.Kroon, Thailand*

#### **Funding and sustainability**

*D.Finzi, United States*

### **Moderated discussion**

### **Conclusion**

## **WEWS04 Publish or Perish: how to write a research manuscript**

Professional Development Workshop

**Venue:** Mini Room 3

**Time:** Wednesday 03 July, 14:30-17:30

**Level:** Foundation

**Target audience:** Researcher, Student, Undergraduate student, Postgraduate student, Post doctoral student

**Seating limit:** 100

**Co-Facilitators:** Shirin Heidari, Switzerland  
Mark Wainberg, Canada  
Papa Salif Sow, Senegal  
Mirjam Curno, Switzerland

This interactive workshop provides an overview of the scientific writing process and an introduction to the publishing process for less-experienced authors. The writing section will cover key components of a scientific manuscript and it will also highlight some of the resources available to authors. The publishing section will describe the publication and the peer-review process, and also address ethical issues in scientific writing. A panel of editors will give an insight into the workings of an editorial office and discuss the most common reasons for rejection of manuscripts. The aim is to make the editorial decision-making process transparent and provide practical information on how to navigate the publication process by avoiding common pitfalls. The workshop will be facilitated by the Journal of the International AIDS Society.

#### **How to write a research manuscript**

*P.Sow, Senegal; M.Wainberg, Canada*

#### **Choosing a journal and submitting a manuscript**

*P.Sow, Senegal*

#### **Editorial decision making and reasons for rejection**

*S.Heidari, Switzerland*

#### **Revising a manuscript**

*M.Wainberg, Canada*

#### **Scientific integrity in publishing**

*M.Curno, Switzerland*

### **Question-answer time with editors' panel**

**WELBC Late Breaker Track C**

## Oral Abstract Session

**Venue:** Session Room 1

**Time:** Wednesday 03 July, 16:30-17:30

**Co-Chairs:** Suwat Chariyalertsak, Thailand  
Elizabeth Bukusi, Kenya

### Implementing Option B+ for prevention of mother to child transmission at Bwaila Maternity Unit, Lilongwe: the first 18 months

C. Speight, S. Phiri, M. Hosseinipour, H. Tweya, F. Chimbwandira, J. Chikonda, M. Phoso, M. Kalulu, A. Chauma  
Malawi

### Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men

R. Grant, V. McMahan, R. Amico, C. Mosquera, O. Montoya, S. Buchbinder, V. Veloso, S. Chariyalertsak, K. Mayer, L.-G. Bekker, M. Schechter, E. Kallas, M. Casapia, J. Guanira, M. Mehrotra, D. Glidden, iPrEx Study Team  
United States

### Acute HIV infection detection and control reduces HIV infectiousness and transmission risk behavior among men who have sex with men in Bangkok, Thailand

F. van Griensven, N. Phanuphak, E.D.M.B. Kroon, J. Fletcher, S. Pinyakorn, N. Chomchey, S. Akapirat, R. Trichavaroj, M. de Souza, J. Kim, J. Ananworanich  
Thailand

### A field study of male circumcision using the Shang Ring, a minimally-invasive disposable device, in routine clinical settings in Kenya and Zambia

M.A. Barone, P.S. Li, R. Zulu, Q.D. Awori, K. Agot, S. Combes, R.O. Simba, R. Lee, C. Hart, J.J. Lai, Z. Zyambo, M. Goldstein, D.C. Sokal  
United States

### The Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Thailand: participant adherence and study results

K. Choopanva, S. Vanichseni, P. Suntharasamai, U. Sangkum, P.A. Mock, M. Leethochawalit, S. Chiamwongpaet, S. Kittimunkong, R. Gvetadze, J. McNicholl, L. Paxton, M. Curlin, M. Martin, Bangkok Tenofovir Study Group  
Thailand

### Moderated discussion

## WELBB Late Breaker Track B

### Oral Abstract Session

**Venue:** Session Room 2

**Time:** Wednesday 03 July, 16:30-17:30

**Co-Chairs:** David Cooper, Australia  
Teresa Branco, Portugal

### A daily dose of 400mg efavirenz (EFV) is non-inferior to the standard 600mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial

R. Puls, Encore1 Study Group  
Australia

### A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial

N. Paton, C. Kityo, A. Hoppe, J. Hakim, J. van Oosterhout, A. Siika, P. Mwaba, A. Kambugu, P. Easterbrook, J. Boles, S. Walker, P. Mugenyi, EARNEST Trial Group  
United Kingdom

### Dolutegravir (DTG) is superior to raltegravir (RAL) in ART-experienced, integrase naive subjects: week 48 results from SAILING (ING11762)

P. Cahu, A.L. Pozniak, H. Mingrone, C. Brites, J.F. Andrade-Villanueva, J. Fourie, M. Ramgopal, D. Hagins, J. Valdez Madruga, T. Newman, J. Lombaard, D. Dorey, M. Underwood, S. Griffith, S. Min  
Argentina

### HLA-B\*35:05 and CCHCR1 screening reduces nevirapine-associated cutaneous adverse reactions in Thailand: a prospective multicenter randomized controlled trial

S. Kiertiburanakul, S. Mahasirimongkol, N. Rajatanavin, A. Charoenyingwattana, A. Rojanawiwat, W. Wangsomboonsiri, W. Manosuthi, P. Kantipong, A. Apisarnthanarak, W. Sangsirinakul, P. Wongprasit, R. Chaiwarith, W. Tantisiriwat, Y. Nakamura, T. Mushiroda, W. Chantratita, S. Sungkanuparph  
Thailand

### Changes in bone mineral density over 48 weeks among participants randomised to either lopinavir/ritonavir (LPV/r) + 2-3N(t)RTI or LPV/r + raltegravir as second-line therapy: a sub-study of the SECONDLIN trial

J. Hoy, A. Martin, C. Moore, P. Mallon, S. Emery, W. Belloso, P. Phanuphak, S. Ferret, D. Cooper, M. Boyd, SECONDLIN study team  
Australia

### Moderated discussion

## WELBD Late Breaker Track D

### Oral Abstract Session

**Venue:** Session Room 3

**Time:** Wednesday 03 July, 16:30-17:30

**Co-Chairs:** Gottfried Hirschall, WHO  
Ng Chiu Wan, Malaysia

### Roll-out of universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ("Option B+") in Malawi: factors influencing retention in care

L.N. Tenthani, A.D. Haas, H. Tweya, A. Jahn, J.J. van Oosterhout, F. Chimbwandira, Z. Chirwa, W. Ng'ambi, A. Bakali, S. Phiri, L. Myer, F. Valeri, M. Zwahlen, G. Wandeler, O. Keiser, IeDEA Southern Africa  
Malawi

### Improved retention in HIV care following SMS reminders in Mozambique: a randomized controlled trial

D. Joseph-Davey, W. Ponce, O. Augusto, D. Traca, E. Jetha, C. de Palha de Sousa  
Mozambique

### The role of routine HIV testing in concentrated epidemics: operations research for optimizing the HIV testing program in an urban Canadian setting

K. Vasarhelyi, S. Kok, J.S.G. Montaner, A.R. Rutherford, R. Barrios, K. McPherson, M. Thumath, L. Tran, A. Nathoo, R. Gustafson  
Canada

### Cost-effectiveness of ART and the Three I's for HIV/TB to prevent tuberculosis in people with HIV

S.S. Gupta, T. Abimbola, A. Date, A. Suthar, R. Bennett, N. Sangrujee, R. Granich  
Switzerland

### Is the pricing of antiretrovirals equitable? Analysis of antiretroviral drug prices in 20 low- and middle-income countries

N. Ford, J. Ananworanich, K. Ruxrungtham, B. Simmons, A. Hill  
United Kingdom

### Moderated discussion

## WELBA Late Breaker Track A

### Oral Abstract Session

**Venue:** Session Room 4

**Time:** Wednesday 03 July, 16:30-17:30

**Co-Chairs:** Daniel Douek, United States  
Sarah Palmer, Australia

### Sustained high levels of circulating galectin-9 despite viral suppression among HIV-infected elite controllers

R. Tandon, T. Fujita, G. Chew, J. Barbour, T. Niki, M. Hirashima, J. Martin, S. Deeks, L. Ndhlovu  
United States

### Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection: the ANRS-EP38-IMMIP study

S. Blanche, D. Scott-Algara, J. Le Chenadec, C. Didier, T. Montange, V. Avettand-Fenoel, C. Rouzioux, J.-P. Viard, C. Dollfus, N. Bouallag, J. Warszawski, F. Busevne  
France

### Gag-positive reservoir cells are identified by a new technique and are susceptible to HIV-specific cytotoxic T lymphocyte

E. Graf, M. Pace, L. Lynch, S. Deeks, S. Migueles, U. O'Doherty  
United States

**HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial**

*J.P. Williams, J. Hurst, N. Robinson, S. Fidler, J. Weber, A. Babiker, R. Phillips, K. Koelsch, T. Kelleher, J. Frater, SPARTAC Trial Investigators*  
United Kingdom

**In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoietic stem cell transplantation**

*T. Henrich, E. Hanhauser, M. Sirignano, B. Davis, T.-H. Lee, S. Keating, M. Busch, F. Marty, A. LaCasce, P. Armand, R. Soiffer, M. Altfeld, D. Kuritzkes*  
United States

**Moderated discussion**

---

**WEPL02 Rapporteur and Closing Session**

Plenary Session

**Venue:** Session Room 1

**Time:** Wednesday 03 July, 17:50-19:30

**Chair:** Bertrand Audoin, Switzerland

**Grant Presentation: Creative and Novel Ideas in HIV Research (CNIHR) Grant Programme**

*F.Barré-Sinoussi, France*

**Conference highlights**

**Track A rapporteur report**

*G.Scarlatti, Italy*

**Track B rapporteur report**

*J.Rockstroh, Germany*

**Track C rapporteur report**

*S.Vermund, United States*

**Track D rapporteur report**

*E.Geng, United States*

**Community statement**

*R.Hamzah, Malaysia*

**Closing remarks**

*F.Barré-Sinoussi, France; A.Kamarulzaman, Malaysia*

**See you in Vancouver!**

*C.Beyrer, United States; J.Montaner, Canada; C.Beyrer, United States; J.Montaner, Canada*

**Canada welcome**

---